Vol 7, No 3 (2011)
Research paper
Published online: 2011-08-23
Validation of selected medical centers involved in molecular diagnostics of cancer in the field of EGFR1 mutations determination
Onkol. Prak. Klin 2011;7(3):138-145.
Abstract
Lung cancer is one of the most common cancers in Poland and abroad. According to statistics, it causes
the death of 1.3 million people per year worldwide. In a nonsmall cell lung cancer (NSCLC), some
patients have somatic mutations in the gene for epidermal growth factor receptor (EGFR), resulting in
a constant activity of this receptor (10–15% patients of North American and Western European origin,
and 30–35% of patients from Japan and Eastern Asia). The occurrence of such mutations is closely
associated with efficacy of tyrosine kinase inhibitors (TKI). Thus, determination of EGFR status is crucial
in selecting the most appropriate treatment of patients with NSCLC.
The aim of this paper is to show whether the laboratories involved in molecular diagnostics for cancer have the potential to effectively determinate the mutation status (in exons 19 and 21) of the EGFR1 gene. An additional objective is to develop appropriate standards for mutation testing in non-small cell lung cancer. As the result of valiadtion process conducted in the study, the following recommendations for diagnostic laboratories were approved: at least 50% of cancer cells should be present in a tissue for DNA isolation; 2. The method of DNA isolation should be standardized, the most appropriate is usage of DNA isolation kits; 3. In case of equivocal results two independent molecular methods should be employed, one of them should be direct sequencing; 4. It is recommended to extend the panel of analyzed exons to 18, 19, 20 and 21; 5 The turnaround time (TAT) should not take more than 10 working days
Onkol. Prak. Klin. 2011; 7, 3: 138–145
The aim of this paper is to show whether the laboratories involved in molecular diagnostics for cancer have the potential to effectively determinate the mutation status (in exons 19 and 21) of the EGFR1 gene. An additional objective is to develop appropriate standards for mutation testing in non-small cell lung cancer. As the result of valiadtion process conducted in the study, the following recommendations for diagnostic laboratories were approved: at least 50% of cancer cells should be present in a tissue for DNA isolation; 2. The method of DNA isolation should be standardized, the most appropriate is usage of DNA isolation kits; 3. In case of equivocal results two independent molecular methods should be employed, one of them should be direct sequencing; 4. It is recommended to extend the panel of analyzed exons to 18, 19, 20 and 21; 5 The turnaround time (TAT) should not take more than 10 working days
Onkol. Prak. Klin. 2011; 7, 3: 138–145
Keywords: lung cancerEGFR mutationsEGFR mutational statustargeted therapymolecular diagnostic